Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury
暂无分享,去创建一个
Han‐Chieh Lin | Yi‐Hsiang Huang | M. Hou | Yun‐Cheng Hsieh | Kuei-Chuan Lee | T. Huo | Pei-Shan Wu | Y. Hsieh
[1] H. Loeffler-Wirth,et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. , 2020, Journal of hepatology.
[2] S. Friedman,et al. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. , 2019, Current opinion in pharmacology.
[3] Han‐Chieh Lin,et al. Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease , 2019, Laboratory Investigation.
[4] L. Vonghia,et al. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease , 2019, Frontiers in Immunology.
[5] Hongliang Li,et al. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease , 2018, Trends in Endocrinology & Metabolism.
[6] K. Zengler,et al. The Role of Intestinal C‐type Regenerating Islet Derived‐3 Lectins for Nonalcoholic Steatohepatitis , 2018, Hepatology communications.
[7] Yong-soo Lee,et al. Hepatocyte toll-like receptor 4 mediates lipopolysaccharide-induced hepcidin expression , 2017, Experimental & Molecular Medicine.
[8] Hongliang Li,et al. Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4 , 2017, Nature Medicine.
[9] Ş. Kızıltaş. Toll-like receptors in pathophysiology of liver diseases , 2016, World journal of hepatology.
[10] Han‐Chieh Lin,et al. Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice , 2016, Scientific Reports.
[11] J. Antoun,et al. Hepatic TLR4 signaling in obese NAFLD. , 2015, American journal of physiology. Gastrointestinal and liver physiology.
[12] E. Bjornsson,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.
[13] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[14] R. Schwabe,et al. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers , 2015, Nature Protocols.
[15] Yuanqing Liu,et al. A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal Species , 2014, Front. Immunol..
[16] J. Elmquist,et al. Hepatocyte Toll-like Receptor 4 Regulates Obesity-Induced Inflammation and Insulin Resistance , 2014, Nature Communications.
[17] J. Odin,et al. Toll‐like receptors and liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[18] T. Billiar,et al. Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma. , 2013, The Journal of surgical research.
[19] J. Vincent,et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.
[20] Derrick E Fouts,et al. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. , 2012, Journal of hepatology.
[21] K. Iwaisako,et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist , 2012, Proceedings of the National Academy of Sciences.
[22] Gang Wang,et al. A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development , 2012, Cytotechnology.
[23] P. Knuefermann,et al. In Vivo Toll-Like Receptor 4 Antagonism Restores Cardiac Function During Endotoxemia , 2011, Shock.
[24] G. Gores,et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[25] A. Dolganiuc,et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[26] D. Brenner,et al. Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease , 2011, Gastroenterology research and practice.
[27] S. Friedman,et al. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis , 2010, Fibrogenesis & tissue repair.
[28] T. Tsujimoto,et al. Salvage effect of E5564, Toll‐like receptor 4 antagonist on d‐galactosamine and lipopolysaccharide‐induced acute liver failure in rats , 2010, Journal of gastroenterology and hepatology.
[29] S. Akira,et al. Pattern Recognition Receptors and Inflammation , 2010, Cell.
[30] G. Gerken,et al. Toll‐like receptor‐induced innate immune responses in non‐parenchymal liver cells are cell type‐specific , 2010, Immunology.
[31] T. F. Murray,et al. Effects of the second-generation synthetic lipid A analogue E5564 on responses to endotoxin in [corrected] equine whole blood and monocytes. , 2008, American journal of veterinary research.
[32] W. Yeh,et al. LPS/TLR4 signal transduction pathway. , 2008, Cytokine.
[33] P. Adegboyega,et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. , 2007, Journal of hepatology.
[34] Hayyoung Lee,et al. Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran , 2007, Cell.
[35] J. Carvalheira,et al. Loss-of-Function Mutation in Toll-Like Receptor 4 Prevents Diet-Induced Obesity and Insulin Resistance , 2007, Diabetes.
[36] A. Simm,et al. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes , 2006, Inflammation Research.
[37] J. Flier,et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.
[38] Christian Jobin,et al. Toll‐Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells , 2003, Hepatology.
[39] F. Gusovsky,et al. Inhibition of Endotoxin Response by E5564, a Novel Toll-Like Receptor 4-Directed Endotoxin Antagonist , 2003, Journal of Pharmacology and Experimental Therapeutics.
[40] D. Rossignol,et al. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue , 2002, Journal of endotoxin research.
[41] Hongliang Li,et al. Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. , 2019, Physiological reviews.
[42] T. Billiar,et al. Toll-like Receptor 4 (TLR4) Antagonist Eritoran Tetrasodium Attenuates Liver Ischemia and Reperfusion Injury through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling , 2015, Molecular medicine.
[43] R. Schwabe,et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. , 2007, Nature medicine.
[44] S. Friedman,et al. Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.
[45] A. B. Sukhomlinov,et al. [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.